<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362620</url>
  </required_header>
  <id_info>
    <org_study_id>CNI-DOC-2014-02</org_study_id>
    <secondary_id>CNIO-CP-02-2014</secondary_id>
    <nct_id>NCT02362620</nct_id>
  </id_info>
  <brief_title>PROSTAC: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Docetaxel or Cabazitaxel.</brief_title>
  <acronym>PROSTAC</acronym>
  <official_title>Prospective Multi-centre Study of Prognostic Factors in Castration-Resistant Prostate Cancer Patients Treated With Docetaxel or Cabazitaxel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Nacional de Investigaciones Oncologicas CARLOS III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Nacional de Investigaciones Oncologicas CARLOS III</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROSTAC is a prospective multi-centre study to analyse circulating and tissue biomarkers that
      may predict prognosis and response in patients with CRPC treated with Docetaxel or
      Cabazitaxel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional prospective study in metastatic CRPC designed to explore
      biomarkers, composed by two cohorts of patients treated with docetaxel or cabazitaxel. Key
      inclusion criteria: a) histological confirmation of prostate cancer; b) documented criteria
      (PCWG2) for CRPC; c) availability of tumour tissue; d) candidate for standard treatment with
      docetaxel or cabazitaxel.

      Primary end point: to validate the prognostic value for overall survival (OS) of the
      expression signature (ES) in peripheral blood of 9 genes described by Olmos et al (Lancet
      Oncol 2012).

      Secondary end points: a) to study the prognostic role for progression-free survival of the
      ES; b) to analyze the prognostic role for OS of early changes in the ES; c) to compare the
      prognostic and predictive utility of the ES with other ES (Ross et al, Lancet Oncol 2012); d)
      to validate in this patient cohort prognostic nomograms described for CRPC.

      Exploratory outcomes: a) to establish prognostic value for TMPRSS-ERG and PTEN; b) to
      determine the prognostic value for serum testosterone levels; c) to analyze the role of serum
      chromogranine; d) to study the prognostic role of AR splicing variants; e) to explore new
      somatic and germinal variants in peripheral blood and tissue associated to dissemination,
      response and resistance to taxanes.

      PROSTAC is part of the PROCURE Biomarkers network, a multicentric spanish platform for
      biomarkers discovery in CRPC patients. 242 patients treated with docetaxel and 160 patients
      treated with cabazitaxel will be accrued to provide appropriate statistical power to analyze
      the main outcome. Blood samples are collected before, during (pre-cycle 3) and after
      progression to taxanes. Prospective data collection will be linked.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To validate the independent prognostic value of the expression signature in peripheral blood of 9 genes described by Olmos et al (Lancet Onco 2012) on overall survival in CRPC patients treated with Docetaxel or Cabazitaxel.</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyze the prognostic value of the expression signature described by Olmos et al (Lancet Oncol, 2012) on PSA progression-free survival and radiological progression-free survival in CRPC patients treated with docetaxel or cabazitaxel.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze the prognostic role of early changes in the expression signature described by Olmos et al (Lancet Oncol, 2012) in CRPC patients treated with docetaxel or cabazitaxel.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the prognostic and predictive value between the expression signature described by Olmos et al (Lancet Oncol, 2012) with other expression signatures (Ross et al, Lancet Oncol, 2012) in CRPC patients treated with docetaxel or cabazitaxel.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To validate in these patients the value of prognostic nomograms described for castration-resistant prostate cancer.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the prognostic value of TMPRSS2-ERG and PTEN status in these cohorts.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze the prognostic role of AR splicing variants, serum chromogranine and serum testosterone levels measured by ultrasensitive method in CRPC patients treated with docetaxel or cabazitaxel.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the correlation between new somatic and germinal variants in peripheral blood and FFPE with response and resistance to taxanes.</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Castration Resistant</condition>
  <condition>Cabacitaxel or Docetaxel</condition>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <description>Docetaxel 75mg/m2 IV every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <description>Cabazitaxel 20-25mg/m2 IV every 3 weeks</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and FFPE tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Castration-Resistant Prostate Cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent.

          2. Patients must be ≥ 18-year-old.

          3. Histologically confirmed prostate cancer.

          4. ECOG Performance Status ≤ 2.

          5. Castration resistance must be documented with surgical or medical castration with
             serum testosterone &lt; 50 ng/mL (&lt; 2.0 nM).

          6. Biochemical progressione upon prior treatment according to PCWG2 criteria.

          7. Candidates for standard treatment with docetaxel 75mg/m2 every 3 weeks or cabazitaxel
             20-25mg/m2 every 3 weeks intravenously.

          8. Availability of formalin-fixed paraffin-embedded blocks from the prostate biopsy
             and/or radical prostatectomy.

          9. Acceptable haematological, hepatic and renal functions.

        Exclusion Criteria:

          1. Previous cancer diagnosis, except those patients who had a localized malignant tumour
             and who are five years cancer-free or those diagnosed with skin cancers (of
             non-melanoma type) or excised in situ carcinomas.

          2. Any prior medical history that according to the judgement of the investigator might
             interfere with the subject´s granting of informed consent or the safe execution of the
             procedures required in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Olmos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Prostate Cancer Clinical Research Unit CNIO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuria Romero, MD, PhD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2950</phone_ext>
    <email>nromerol@cnio.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Isabel Pacheco, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2951</phone_ext>
    <email>mipacheco@ext.cnio.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urbano Anido, MD</last_name>
      <phone>+34981950000</phone>
      <email>urbanoanido@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M. Piulats, MD</last_name>
      <phone>+34932607780</phone>
      <email>jmpiulats@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Althaia Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Domenech, MD</last_name>
      <phone>+34938759300</phone>
      <phone_ext>3309</phone_ext>
      <email>mdomenech@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Viciana, MD</last_name>
      <phone>+34956032075</phone>
      <email>ruthvician@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Villatoro, MD</last_name>
      <phone>+34951976470</phone>
      <email>villatororoldan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Lainez, MD</last_name>
      <phone>+34948255400</phone>
      <phone_ext>5870</phone_ext>
      <email>nuria.lainez.milagro@cfnavarra.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Delia Garcia, MD</last_name>
      <phone>+34922678204</phone>
      <email>rdgmarrero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Centro Oncologico de Galicia</name>
      <address>
        <city>A Coruna</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Medina, MD</last_name>
      <phone>+34981287499</phone>
      <phone_ext>174</phone_ext>
      <email>ana.medina@cog.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Morales, MD</last_name>
      <phone>+34932746000</phone>
      <phone_ext>4695</phone_ext>
      <email>rafael.morales.barrera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Carlos Villa, MD</last_name>
      <phone>+34926278000</phone>
      <phone_ext>77137</phone_ext>
      <email>jvillaguzman1@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Mendez, MD</last_name>
      <phone>+34957011147</phone>
      <email>mjosemv@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Luque, MD</last_name>
      <phone>+34958020000</phone>
      <email>rluquecaro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Casinello, MD</last_name>
      <phone>+34949209200</phone>
      <email>jacaes@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Angel Arranz, MD</last_name>
      <phone>+34914269070</phone>
      <email>jarranz@oncomed.gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coordination PROCURE-Centro Nacional de Investigaciones Oncologicas</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Romero, MD</last_name>
      <phone>347328000</phone>
      <phone_ext>2951</phone_ext>
      <email>nromerol@cnio.es</email>
    </contact>
    <contact_backup>
      <last_name>Berta Nasarre, PhD</last_name>
      <email>bnasarre@cnio.es</email>
    </contact_backup>
    <investigator>
      <last_name>Leticia Rivera, CRA senior</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gala Grau, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Isabel Pacheco, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Garces, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puente, MD</last_name>
      <phone>+34913303000</phone>
      <phone_ext>7332</phone_ext>
      <email>docjavip@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Castellanos, MD</last_name>
      <phone>+34913908339</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Francisco Rodriguez Moreno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Romero, MD</last_name>
      <email>ecastro@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Juan Francisco Rodríguez-Moreno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anatomical Pathology PROCURE</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isabel Hierro, Prof</last_name>
      <phone>+34951032000</phone>
      <email>misabel.hierro.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Ines de Torres, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Montesa, MD</last_name>
      <phone>+34951291425</phone>
      <email>amontesa@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gonzalez, MD</last_name>
      <phone>+34968360900</phone>
      <phone_ext>3807</phone_ext>
      <email>engonbil@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Isabel Sáez, MD</last_name>
      <email>msaez.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aranzazu Gonzalez, MD</last_name>
      <phone>+34871206130</phone>
      <phone_ext>76130</phone_ext>
      <email>aranzazu.gonzalezdealba@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Azpitarte, MD</last_name>
      <phone>+34 986800004</phone>
      <email>crisazpi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lorente, MD</last_name>
      <phone>+34961244000</phone>
      <email>davlorente@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castration Resistant Prostate Cancer, Biomarkers, Taxanes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

